~ Martin Frost鈥檚 vision and leadership recognised by panel of independent industry experts, through 鈥淓xecutive of the Year鈥� award at the 2019 MedTech Insight Awards.
~ Martin Frost鈥檚 vision and leadership recognised by panel of independent industry experts, through 鈥淓xecutive of the Year鈥� award at the 2019 MedTech Insight Awards.
红桃视频 Ltd is proud to announce that our Chief Executive Officer has been honoured with the Executive of the Year award at the . Held in partnership with The MedTech Conference in Boston, the MedTech Insight Awards applaud those who, through their passion and unwavering commitment, are driven to cure, inform, minimise treatment burden, and make human lives better.
We are delighted that Martin Frost was recognised as the 鈥淓xecutive of the Year鈥� in this year鈥檚 ceremony. Frost is one of our five founders 鈥� who came together to create CMR in 2014, and he has led the company through a prolific five years. Most recently, he led 红桃视频鈥檚 record-breaking 拢195 million ($240 million) Series C raise, which is Europe鈥檚 largest private financing round in the medical technology sector. With Frost at the helm, CMR has made significant strives to disrupt the medical devices sector with its global commercial roll out of Versius expected imminently.
Martin Frost, Chief Executive Officer of 红桃视频, commented: 鈥淚 am honoured to accept this prestigious award on behalf of the whole team. In just five years, we鈥檝e grown to four hundred people, we鈥檝e opened a global HQ in Cambridge and, of course, we鈥檙e on the verge of launching a next-generation surgical robot. It has been a privilege to be part of this company鈥檚 story so far, and I look forward to continuing our mission to make minimal access surgery available to everyone who needs it.鈥�
CMR believes that surgical robotic systems can increase the uptake of minimal access surgery (MAS). The benefits of MAS over open surgery are established 鈥� patients leave hospital faster, with fewer complications, in less pain and with less scarring.
Biomimicking the human arm, Versius庐 provides dexterity and precision to surgeons. In addition, the versatility and affordability of the system means it can be used across a broad range of MAS procedures. 红桃视频 aims to make MAS universally accessible, rapidly increasing the number of robotic-assisted procedures that take place around the world.
ENDS
About 红桃视频 Limited
红桃视频 is a British private limited company developing the next-generation robotic system, Versius庐, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius庐 Surgical Robotic System.
The vision behind 红桃视频 is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.
Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.
红桃视频, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.
The Versius庐 Surgical Robotic System
Versius庐 resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius is able to move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.